Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: Case report

Journal of Chemotherapy

Volumn 17, Issue 3, 2005, Pages 343-346

  Mohiuddin, Majid M ^a   Harmon, D C ^a   Delaney, T F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bortezomib; Multiple myeloma; Radiotherapy; Velcade

Indexed keywords

ATROPINE PLUS DIPHENOXYLATE; BORTEZOMIB; DEXAMETHASONE; LOPERAMIDE; ONDANSETRON; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; ANAMNESIS; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; DIARRHEA; ENTERITIS; FEMALE; HUMAN; LOW BACK PAIN; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; PALLIATIVE THERAPY; PARESTHESIA; PLASMACYTOMA; RADIATION DOSE; SPINE FRACTURE; VOMITING;

EID: 22244464246     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.3.343     Document Type: Article

References (23)

1. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9: 6316-6325.
2. Lee SJ, Dimtchev A, Lavin MF, Dritschilo A, Jung M. A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-kappaB. Oncogene 1998; 17: 1821-1826.
3. McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F. The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 2003; 22: 5755-5773.
4. McBride WH, Pajonk F, Chiang CS, Sun JR. NF-kappa B, cytokines, proteasomes, and low-dose radiation exposure. Mil Med 2002; 167: 66-67.
5. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638-2645.
6. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
7. Yang H, Hermann JL, Logothetis CJ, et al. Enhanced induction of prostate carcinoma cell death by inhibition of proteasomal activity using the novel dipeptidyl boronate PS-341 in combination with ionizing radiation; modulation by bcl-2. Clin Cancer Res 1999; 5 (Supp): 3770s-#204.
8. Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002; 1: 1243-1253.
9. Pajonk F, Pajonk K, McBride WH. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 2000; 47: 1025-1032.
10. Pajonk F, Pajonk K, McBride WH. Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst 1999; 91: 1956-1960.
11. Schenkein D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma 2002; 3: 49-55.
12. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
13. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 2505-2511.
14. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR. Integration of the proteasome inhibitor PS-341 (velcade) into the therapeutic approach to lung cancer. Lung Cancer 2003; 41 Suppl 1: S89-96.
15. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420-4427.
16. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
17. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation, myeloma subcommittee of the EBMT. European group for blood and marrow transplant. Br J Haematol 1998; 102: 1115-1123.
18. Russo SM, Tepper JE, Baldwin AS, Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 183-193.
19. Kim KM, Zhang Y, Kim BY, et al. The p65 subunit of nuclear factor-kappaB is a molecular target for radiation sensitization of human squamous carcinoma cells. Mol Cancer Ther 2004; 3: 693-698.
20. Wang CY, Cusack JC, Jr, Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature Med 1999; 5: 412-417.
21. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419-1428.
22. Dritschilo A. Radiosensitivity and transcription factor NF-kappaB inhibition-progress and pitfalls. J Natl Cancer Inst 1999; 91: 1910-1911.
23. Harbison MT, Bruns CJ, Bold RJ, et al. Proteasome inhibitor PS-341 effective as an anti-angiogenic agent in the treatment of human pancreatic cancer via the inhibition of NF-kB and subsequent inhibition of vascular endothelial growth factor production. Clin Cancer Res 1999; 5 (Supp): 3812s-#414.